Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 7
2004 12
2005 7
2006 7
2007 8
2008 13
2009 6
2010 8
2011 25
2012 19
2013 17
2014 28
2015 18
2016 15
2017 12
2018 29
2019 21
2020 21
2021 24
2022 42
2023 23
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Results by year

Filters applied: . Clear all
Page 1
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu XD, Bai D, Chen Y, Chen Y, Dai C, Guo R, Guo W, Hao C, Huang T, Huang Z, Li D, Li G, Li T, Li X, Li G, Liang X, Liu J, Liu F, Lu S, Lu Z, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan C, Wang G, Wang L, Wang S, Wen T, Xing B, Xiang B, Yan S, Yang D, Yin G, Yin T, Yin Z, Yu Z, Zhang B, Zhang J, Zhang S, Zhang T, Zhang Y, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Z, Qin S, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng S, Fan J; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Sun HC, et al. Among authors: zhu z. Hepatobiliary Surg Nutr. 2022 Apr;11(2):227-252. doi: 10.21037/hbsn-21-328. Hepatobiliary Surg Nutr. 2022. PMID: 35464283 Free PMC article. Review.
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
Yang Y, Sun J, Wu M, Lau WY, Zheng S, Wang XH, Chen X, Fan J, Dong J, Cai J, Chen M, Chen Y, Cheng Z, Dai C, Shan J, Du CY, Fang C, Hu H, Ji Z, Jia W, Li G, Li J, Li J, Liu C, Liu F, Ma Y, Mao Y, Niu Z, Shen J, Shi J, Shi X, Song W, Sun HC, Tan G, Tao R, Wang X, Wen T, Wu L, Xia J, Xiang BD, Yan M, Ying M, Zhang L, Zhang X, Zeng ZC, Zhang Y, Zhang Z, Zhou J, Zhou C, Zhou J, Zhou L, Zhou X, Zhu J, Zhu Z, Zhang Q, Li Q, Cheng S. Yang Y, et al. Among authors: zhu z. Liver Cancer. 2022 Jul 20;11(6):511-526. doi: 10.1159/000526038. eCollection 2022 Dec. Liver Cancer. 2022. PMID: 36589726 Free PMC article. Review.
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC.
Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X. Yu S, et al. Among authors: zhu z. J Hepatocell Carcinoma. 2022 Aug 26;9:855-867. doi: 10.2147/JHC.S377768. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 36051860 Free PMC article. Review.
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, Yang X, Xun Z, Chao J, Long J, Sang X, Zhu Z, Zhao H. Zhu C, et al. Among authors: zhu z. Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37247023 Free PMC article.
335 results